Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.014 +0.030 (+3.03%)
Streaming Delayed Price Updated: 11:22 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition
Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Diarrheal Disorder at 2022 Digestive Disease Week
Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index
"Canine Cancer: Take C.H.A.R.G.E." (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical Records 
From Jaguar Health, Inc.
Via AccessWire
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
Click here to RSVP for this in-person, outdoor event 
From Jaguar Health, Inc.
Via AccessWire
Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!
Click Here To RSVP for This In-Person, Outdoor Event Human and Doggy Swag Will Be Available*, and the Event Will Feature Presentations by Well-Known Veterinary Cancer Specialists, Including Dr. Sue... 
From Jaguar Health, Inc.
Via AccessWire
Why Is Jaguar Health (JAGX) Stock Up Today?
Here's the big partnership news that's taking shares of Jaguar Health and JAGX stock soaring in afternoon trading today. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another busy week of trading as we start it off with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
30 Stocks Moving in Monday's Pre-Market Session
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday. 
Via Benzinga
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 89.7% to $0.1480 in pre-market trading after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health
SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company. The paid report... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Launch of Mytesi Telehealth Program
This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials
Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021 Core initiatives: -... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 6, 2022, the Company granted 50,000 restricted stock... 
From Jaguar Health, Inc.
Via AccessWire
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
We Asked, You Answered: What Stock Would You Never Buy Again?
Almost all traders have had that moment: A confident stock pick or strategy that backfires and leaves the investor with less money than they had before and vowing never to trade that stock again. 
Via Benzinga
Jaguar Health, Inc. (NASDAQ: JAGX) Featured in Coverage of NobleCon18
Via Investor Brand Network
Exposures Product Safety
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer
Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with... 
From Jaguar Health, Inc.
Via AccessWire
Here's Why Jaguar Health Shares Are Rising
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 10.90% at $0.70 on continued momentum after the company last week announced an agreement granting Quadri Pharmaceuticals for exclusive... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
Via Benzinga
Here's Why Jaguar Health Shares Are Popping Off
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 31.2% at $0.70 after the company announced an agreement granting Quadri Pharmaceuticals for exclusive promotional, commercialization and... 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human... 
From Jaguar Health, Inc.
Via AccessWire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.